Skip to content
PARTICIPER À UNE ÉTUDELISTE DE DIFFUSION
X page opens in new window
AB SCIENCE
Discipline serving the patients
AB SCIENCE
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • FR
  • EN
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Category Archives: 2019

You are here:
  1. Home
  2. News
  3. Category "2019"

Publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal ALSFD

2019By Alexis BERNARD8 July 2019

08/07/2019 – AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedure

2019By Alexis BERNARD4 July 2019

04/07/2019 – AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.

Results of interim analysis for masitinib in Alzheimer’s Disease

2019By Alexis BERNARD26 June 2019

26/06/2019 – AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease

June 14 2019 web conference presentation

2019By Alexis BERNARD14 June 2019

14/06/2019 – AB Science web conference presentation

Positive IDMC recommendation following interim analysis in pancreatic cancer

2019By Alexis BERNARD12 June 2019

12/06/2019 – AB Science announces the positive recommendation of IDMC following the interim analysis of AB12005 study in the first-line treatment of pancreatic cancer

Upcoming news flow

2019By Alexis BERNARD10 June 2019

10/06/2019 – AB Science is providing the upcoming news flow of the Company

Updated corporate overview

2019By Alexis BERNARD10 June 2019

10/06/2019 – AB Science is providing an updated coporate overview of the Company

Summary of the webconference held on June 5, 2019

2019By Alexis BERNARD5 June 2019

05/06/2019 – AB Science is providing a summary of the web conference held on 5 June, 2019

June 5 2019 web conference presentation

2019By Alexis BERNARD5 June 2019

05/06/2019 – AB Science web conference – Part 2

Summary of the webconference held on June 4, 2019

2019By Alexis BERNARD4 June 2019

04/06/2019 – AB Science is providing a summary of the web conference held on 4 June, 2019

←1234→
© 2026 AB SCIENCE
Go to Top